Radar on Market Access: Zeposia May Have Challenges Within Ulcerative Colitis Class

On May 27, the FDA gave an additional indication to Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis. It is the first and only sphingosine 1-phosphate (S1P) receptor modulator approved for this indication. However, according to payers responding to a survey by Zitter Insights, the treatment may have some challenges breaking into the space, AIS Health reported . How much will Zeposia cost?

Read the source article at Welcome
2021-07-15 14:45:31